Literature DB >> 12874614

Multivariate associates of QT interval parameters in diabetic patients with arterial hypertension: importance of left ventricular mass and geometric patterns.

G F Salles1, C R L Cardoso, W Deccache.   

Abstract

The aim of the study was to assess the determinants of increased QT interval parameters in diabetic patients with arterial hypertension and, in particular, the strength of their relationships to echocardiographically derived left ventricular mass (LVM) and geometric patterns. In a cross-sectional study with 289 hypertensive type 2 diabetic outpatients, maximal QT and QTc (heart rate-corrected) intervals, and QT, QTc, and number-of-leads-adjusted QT interval dispersions were manually measured from standard baseline 12-lead ECGs. Electrocardiographic criteria for left ventricular hypertrophy (LVH) were either Sokolow-Lyon or Cornell sex-specific voltages. LVM and geometric patterns were determined by 2D echocardiography. Statistical analyses involved bivariate tests (Mann-Whitney, chi2, Spearman's correlation coefficients, ANOVA and receiver-operating-characteristic (ROC) curve analyses) and multivariate tests (multiple linear and logistic regressions). QT dispersion measurements showed significant correlations with echocardiographic LVM (r=0.26-0.27). ROC curves demonstrated a poor isolated predictive performance of all QT parameters for detection of LVH (areas under curve: 0.58-0.59), comparable to that of electrocardiographic voltage criteria. Only patients with concentric hypertrophy had significantly increased QT dispersion (QTd) when compared to those with normal geometries (64.24+/-21.09 vs 53.20+/-15.35, P<0.05). In multivariate analyses, both electrocardiographic and echocardiographic LVH were independent predictors of increased QTd, as well as only QTd and gender were determinants of LVM. In conclusion, increased QT interval dispersion is associated with LVM and concentric hypertrophy geometric pattern in diabetic hypertensive patients, although in isolation neither QTd nor any QT parameter presents enough predictive performance to be recommended as screening procedures for detection of LVH.

Entities:  

Mesh:

Year:  2003        PMID: 12874614     DOI: 10.1038/sj.jhh.1001590

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  5 in total

Review 1.  Effects of Bariatric Surgery on Heart Rhythm Disorders: a Systematic Review and Meta-Analysis.

Authors:  Elijah E Sanches; Besir Topal; Frank W de Jongh; Eylem Cagiltay; Alper Celik; Magnus Sundbom; Rui Ribeiro; Chetan Parmar; Surendra Ugale; Kamal Mahawar; Marc P Buise; Lukas R Dekker; Dharmanand Ramnarain; Sjaak Pouwels
Journal:  Obes Surg       Date:  2021-03-13       Impact factor: 4.129

2.  Declining Levels and Bioavailability of IGF-I in Cardiovascular Aging Associate With QT Prolongation-Results From the 1946 British Birth Cohort.

Authors:  Christos Charalambous; James C Moon; Jeff M P Holly; Nishi Chaturvedi; Alun D Hughes; Gabriella Captur
Journal:  Front Cardiovasc Med       Date:  2022-04-22

3.  Reproducibility and Reliability Of QTc and QTcd Measurements and Their Relationships with Left Ventricular Hypertrophy in Hemodialysis Patients.

Authors:  Maria Angélica Gonçalves Alonso; Valentine de Almeida Costa de Castro Lima; Maria Angela Magalhães de Queiroz Carreira; Jocemir Ronaldo Lugon
Journal:  Arq Bras Cardiol       Date:  2017-08-07       Impact factor: 2.000

4.  The relationship between insulin sensitivity and heart rate-corrected QT interval in patients with type 2 diabetes.

Authors:  Xiao-Hua Yang; Jian-Bin Su; Xiu-Lin Zhang; Li-Hua Zhao; Feng Xu; Xue-Qin Wang; Xing-Bo Cheng
Journal:  Diabetol Metab Syndr       Date:  2017-09-11       Impact factor: 3.320

5.  The relationship between adenosine deaminase and heart rate-corrected QT interval in type 2 diabetic patients.

Authors:  Chun-Feng Lu; Xiao-Qin Ge; Yan Wang; Jian-Bin Su; Xue-Qin Wang; Dong-Mei Zhang; Feng Xu; Wang-Shu Liu; Min Su
Journal:  Endocr Connect       Date:  2021-08-03       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.